Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06353126 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DEB-TACE Prior to Liver Transplantation in the Treatment of HCC

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 18, 2024 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 1, 2024 to Oct 16, 2024
    v5
  2. Phase: Phase 2 to Phase 4
    • Start date: Aug 1, 2024 to Oct 1, 2024
    • Secondary endpoints revised (4)
    • Eligibility criteria expanded, about 3 words
    v4
  3. Start date: Jun 1, 2024 to Aug 1, 2024
    • Eligibility criteria expanded, about 109 words
    • Collaborators expanded, about 3 words
    v3
  4. Collaborators shortened, about 3 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
RenJi Hospital
190 trials monitored
See 2 trials at risk
Liver Cancer
1,598 trials monitored
See 71 trials at risk
The goal of the study is to explore whether the usage of DEB-TACE (Drug-Eluting Bead Transarterial Chemoembolization) prior to living donor liver transplantation can prolong the recurrence-free survival in patients with hepatocellular carcinoma (HCC). It is a single-center, exploratory study. The patients scheduled for living donor liver transplantation receive DEB-TACE 2 weeks prior to the surgery. The primary outcome: Recurrence-free survival (RFS) The secondary outcome:1) Overall survival (OS)；2) Pathological response rate (Pathological Response); 3) Proportion of patients completing living donor liver transplantation; 4) Adverse events related to DEB-TACE.
Trial Details
NCT Number NCT06353126
Lead Sponsor RenJi Hospital
Collaborators: Boston Scientific Corporation
Conditions
(from sponsor)		 Liver Cancer
Related terms Liver Neoplasms
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov